Equity · Healthcare
ORKA
NASDAQOruka Therapeutics (ORKA)
The line runs 108 USD on 13 August through 94 USD on 16 September, on a scale from 90 to 120. Days the market did not trade hold the previous close, flat.
- Market cap
- 6.4B USD
- 52-week range
- 14.86 USD – 113 USD
- Avg volume
- 96.4K
as of Sep 16, 2026
Have Oruka Therapeutics (ORKA) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, Oruka Therapeutics insiders reported 18 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 21 May 2026, show no open-market purchase.
Form 4, 90 days to 11 Nov 2026, newest reported trade 2 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Klein Lawrence OttoChief Executive Officer | Sell | 25,000 | 2.4M USD |
| 20 Oct 2026 | Quinlan Paul TGeneral Counsel | Sell | 9,000 | 707K USD |
| 15 Oct 2026 | Goncalves JoanaChief Medical Officer | Sell | 7,000 | 524K USD |
| 12 Oct 2026 | Agarwal ArjunSenior Vice President, Finance | Sell | 9,999 | 806K USD |
| 01 Oct 2026 | Klein Lawrence OttoChief Executive Officer | Sell | 25,000 | 2.1M USD |
| 21 Sep 2026 | Agarwal ArjunSenior Vice President, Finance | Sell | 533 | 51K USD |
| 21 Sep 2026 | Quinlan Paul TGeneral Counsel | Sell | 10,000 | 936K USD |
| 15 Sep 2026 | Agarwal ArjunSenior Vice President, Finance | Sell | 560 | 54K USD |
| 15 Sep 2026 | Goncalves JoanaChief Medical Officer | Sell | 7,947 | 734K USD |
| 15 Sep 2026 | Klein Lawrence OttoChief Executive Officer | Sell | 2,452 | 235K USD |
| 15 Sep 2026 | Sandler Laura LeeChief Operating Officer | Sell | 906 | 87K USD |
| 15 Sep 2026 | Quinlan Paul TGeneral Counsel | Sell | 1,039 | 99K USD |
| Sold | 18 open-market sales | 257,895 | $24.42M |
Showing the 12 most recent of 18 open-market trades in this window. The figures above count all of them.
14 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Klein Lawrence OttoChief Executive Officer | Option exercise | 25,000 | 195K USD |
| 20 Oct 2026 | Quinlan Paul TGeneral Counsel | Option exercise | 9,000 | 70K USD |
| 15 Oct 2026 | Goncalves JoanaChief Medical Officer | Option exercise | 7,000 | 51K USD |
| 12 Oct 2026 | Agarwal ArjunSenior Vice President, Finance | Option exercise | 9,999 | 157K USD |
| 01 Oct 2026 | Klein Lawrence OttoChief Executive Officer | Option exercise | 25,000 | 195K USD |
| 21 Sep 2026 | Quinlan Paul TGeneral Counsel | Option exercise | 10,000 | 78K USD |
| 15 Sep 2026 | Goncalves JoanaChief Medical Officer | Option exercise | 7,000 | 51K USD |
| 11 Sep 2026 | Agarwal ArjunSenior Vice President, Finance | Option exercise | 9,459 | 150K USD |
| 01 Sep 2026 | Klein Lawrence OttoChief Executive Officer | Option exercise | 75,000 | 585K USD |
| 01 Sep 2026 | Sandler Laura LeeChief Operating Officer | Option exercise | 5,000 | 39K USD |
| 24 Aug 2026 | Edwards Larry ToddChief Commercial Officer | Award | 100,000 | |
| 17 Aug 2026 | Goncalves JoanaChief Medical Officer | Option exercise | 7,000 | 51K USD |
Showing the 12 most recent of 14 compensation filings in this window. The figures above count all of them.
Which funds hold Oruka Therapeutics (ORKA)?
1 of the 45 institutional funds we track reported a Oruka Therapeutics position for the quarter ended 30 Sep 2026 — a combined 18.0M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Added | 215,593 | 18.0M USD | +217.6% |
What has been filed or recorded for Oruka Therapeutics (ORKA)?
The filings we hold for Oruka Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 3 reported financial figures, the latest dated 01 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 62,016 shares | 5.2M USD notional · 0.094% of shares out |
| 30 Sep 2026 | Financials | Total assets | 1.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.2B USD | at period end |
| 31 Dec 2025 | Financials | Net income | −105.4M USD | fiscal year |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.46 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.40 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.87 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.46 USD | |
| 30 Jun 2024 | Quarterly earnings | Q2 2024 reported | EPS −6.96 USD | |
| 31 Mar 2024 | Quarterly earnings | Q1 2024 reported | EPS −2.21 USD | |
| 31 Dec 2023 | Annual report | FY 2023 reported | EPS −0.37 USD | |
| 30 Sep 2023 | Quarterly earnings | Q3 2023 reported | EPS −0.10 USD |
What do people ask about Oruka Therapeutics (ORKA)?
What did Oruka Therapeutics shares close at?94.00
Oruka Therapeutics closed at 94.00 USD on 16 Sep 2026, up 2.17% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Oruka Therapeutics’ market cap?6.4B
Oruka Therapeutics is worth 6.4B USD by market value as of 16 Sep 2026, which is the share price times the shares on issue from its SEC filings.
Have Oruka Therapeutics insiders bought or sold shares recently?18 sales
In the 90 days to 11 Nov 2026, Oruka Therapeutics insiders reported 18 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 21 May 2026, show no open-market purchase. A further 14 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Oruka Therapeutics?1 of 45
1 of the 45 funds we track reported a Oruka Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Oruka Therapeutics last report earnings?−0.46
Oruka Therapeutics last reported earnings on 30 Jun 2025 for Q2 2025, with EPS of −0.46 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings